SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: Biotech Summit 2026Date: Wednesday, February 11, 2026Fireside Chat: 4:30 p.m. ETLocation: New York, NY World ADC London 2026Date: Wednesday, February 25, 2026Presentation: 5:00 p.m. GMTLocation: London, UK Additional in ...

Core Insights - CytomX Therapeutics, Inc. (CTMX) is recognized as one of the best biotech stocks under $20, ranking eighth on a compiled list [1] - Analysts have raised price targets for CTMX, indicating positive sentiment ahead of upcoming data releases related to colorectal cancer treatments [2][3] Group 1: Analyst Ratings and Price Targets - Piper Sandler increased its price target on CTMX to $10 from $6.50, maintaining an Overweight rating, citing a 28% overall response rate and a 94% disease control rate from initial Phase 1 data [2] - Barclays analyst raised the price target for CTMX to $8 from $6, also maintaining an Overweight rating, highlighting an attractive risk-reward profile due to imminent readouts on colorectal cancer [3] Group 2: Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Probody therapeutics, which are designed to enhance cancer targeting and minimize off-tumor toxicity [4] - The company's pipeline includes innovative immuno-oncology and targeted therapies aimed at improving safety and efficacy for solid tumors and other serious diseases [4]

James Bennett, Charlie Moran, and Mike Raffetto of CBRE represented Wareham Development in lease negotiations. CytomX was represented by Paul McManus and Tucker Forbes of Colliers. EmeryStation West is a world-class 265,000 s.f., 9-story research building that forms an integral part of Wareham Development's EmeryStation Research Campus, a 2M s.f. transit and community-oriented campus surrounded by retail and lifestyle amenities and housing. The building is adjacent to the Emeryville Amtrak station, the clos ...

Core Insights - CytomX Therapeutics (CTMX) shares increased by 30.8% over the past month due to strategic business updates and pipeline goals for 2026, with positive clinical progress likely boosting investor confidence [1][7] Pipeline Developments - CytomX's revenue primarily comes from collaboration agreements with companies such as Amgen, Astellas, Bristol Myers, Moderna, and Regeneron [2] - The lead program, Varseta-M (EpCAM PROBODY ADC), is in a phase I study for advanced metastatic colorectal cancer (CRC), with enrollment ongoing and updates expected in Q1 2026 [3][4] - Ongoing phase I dose-expansion studies for Varseta-M are evaluating doses of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, which will inform a potential registrational study design with the FDA planned for later in 2026 [4] - CytomX is also exploring Varseta-M in combination with Roche's Avastin for CRC, with a phase I study expected to start in Q1 2026 and data anticipated in H1 2027 [5] Market Context - Roche's Avastin, a legacy cancer drug, generated CHF 763 million in sales in the first nine months of 2025, although sales are declining due to biosimilar competition [6] - Over the past six months, CytomX shares surged by 126.4%, significantly outperforming the industry average increase of 22.6% [6] Additional Pipeline Updates - CytomX is developing CX-801 (PROBODY Interferon-alpha 2b) as a monotherapy and in combination with Merck's Keytruda for advanced melanoma, with initial clinical data expected by the end of 2026 [8][9] - Keytruda generated $23.3 billion in sales for Merck in the first nine months of 2025, highlighting its significance in the oncology market [8]

Core Viewpoint - CytomX is focused on advancing its unique Probody therapeutic platform in oncology, aiming to enhance the therapeutic window of treatments [2][3]. Company Overview - CytomX is a South San Francisco-based biotech company specializing in oncology, with over 15 years of experience in developing and optimizing its Probody therapeutic platform [3]. Pipeline Development - The company is committed to building a highly differentiated pipeline, with expectations for continued progress in 2026 following a successful 2025 [2].

CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Industry**: Oncology-focused biotechnology - **Location**: South San Francisco - **Key Personnel**: - Sean McCarthy (CEO) - Chris Ogden (CFO) - Rachel Lester (Chief Business Officer) - Wayne Chu (Chief Medical Officer) Core Points and Arguments Pipeline and Technology - CytomX has developed a unique Probody therapeutic platform aimed at masking antibodies to improve therapeutic windows in oncology [3][4] - The company is focused on two main clinical programs: - **Vasetatag masatikan (Vaseta M)**: An EpCAM-targeting Probody Topo-1 ADC for colorectal cancer [3][5] - **CX801**: A Probody version of interferon alpha-2b for melanoma [3][6] Financial Position - CytomX is well-funded, with cash reserves extending into Q2 2027, excluding potential milestones or new business developments [4] Vaseta M Program - The phase one study for Vaseta M is expanding to over 100 patients, with data updates expected by the end of Q1 2026 [8][19] - Initial data showed a 28% confirmed overall response rate and 94% disease control in late-line colorectal cancer patients [14][17] - The market for colorectal cancer is significant, with 1.9 million patients diagnosed annually, projected to exceed 3 million by 2040, and a $5 billion market opportunity in the U.S. for late-line treatment [10][22] Safety and Efficacy - Vaseta M demonstrated a favorable safety profile with no classic EpCAM toxicities, which have historically limited other EpCAM-targeting therapies [15][18] - The most common adverse event reported was grade 3 diarrhea, occurring in 21-22% of patients, which the company is actively investigating [19][36] Future Development Plans - CytomX aims to initiate a combination study of Vaseta M with bevacizumab to explore earlier lines of treatment [20][30] - The company plans to expand into other tumor types where EpCAM is expressed, potentially leading to a pan-tumor agnostic label [21][22] CX801 Program - CX801 is being developed as a novel immunotherapy for melanoma, particularly in patients who have progressed on checkpoint inhibitors [23][26] - The program aims to harness the activity of interferon alpha-2b while minimizing systemic toxicity through masking strategies [24][25] - Initial data from the combination with Keytruda is expected by the end of 2026 [30] Additional Important Content - CytomX has established partnerships with major pharmaceutical companies, including BMS, Amgen, and Moderna, enhancing its business development capabilities [4] - The company emphasizes the importance of understanding the etiology of adverse events, particularly gastrointestinal toxicities, to optimize patient management [37][38] - The strategic decision to focus on colorectal cancer was based on the abundance of the EpCAM target and the unmet medical need in this area [40][41] Conclusion CytomX Therapeutics is positioned at the forefront of innovation in oncology with its differentiated pipeline and strategic focus on unmet needs in colorectal cancer and melanoma. The upcoming data releases and ongoing studies are critical for validating the efficacy and safety of its lead programs, which could significantly impact the treatment landscape in these areas.

Unmasking Advances in Oncology 44th Annual JP Morgan Healthcare Conference Dr. Sean McCarthy, CEO and Chairman January 14, 2026 © 2026 CytomX Therapeutics, Inc. 1 Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events, including those related to varsetatug masetecan and CX-801. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, techno ...

Core Insights - CytomX Therapeutics is advancing its clinical programs, particularly focusing on Varsetatug masetecan (Varseta-M) and CX-801, with significant milestones expected in 2026 [1][2][3] Clinical Program Updates - Varseta-M Phase 1 expansion data is on track for release in Q1 2026, with a combination study with bevacizumab in colorectal cancer (CRC) set to begin in Q1 2026 [1][4] - The total enrollment for the Varseta-M Phase 1 study is projected to reach approximately 100 patients by the planned update in Q1 2026 [6] - The company aims to align with the FDA in 2026 regarding a potential registrational study design for Varseta-M monotherapy in advanced CRC [6] - CX-801 Phase 1 study is ongoing, focusing on advanced melanoma, with monotherapy dose escalation having reached the fourth dose level [6] - Initial clinical data for CX-801 in combination with KEYTRUDA is anticipated by the end of 2026 [6] Strategic Focus - The company is committed to advancing Varseta-M towards a registrational trial in late-line CRC and aims to move it into earlier lines of treatment to address high unmet medical needs [2][3] - CytomX is leveraging its PROBODY therapeutic platform to progress a broader pipeline of therapeutics, including CX-801 [3][8] Upcoming Events - CytomX will present at the 44th Annual JP Morgan Healthcare Conference on January 14, 2026 [1][7]

Core Viewpoint - CytomX Therapeutics, Inc. (NASDAQ:CTMX) is gaining attention as a promising investment opportunity, particularly as it approaches significant clinical data readouts for its CX-2051 therapy in colorectal cancer, with bullish ratings from Piper Sandler and H.C. Wainwright [1][2][3] Group 1: Analyst Ratings and Price Targets - Piper Sandler reaffirmed a Buy rating on CytomX with a price target of $6.50 [1] - H.C. Wainwright reiterated a Buy rating with a higher price target of $10, indicating strong confidence in the company's upcoming data [2] Group 2: Performance Benchmarks for CX-2051 - H.C. Wainwright outlined optimistic performance benchmarks for CX-2051, expecting an objective response rate of 25% to 30% or higher, median progression-free survival of at least six months, and Grade 3 diarrhea in less than 5% of patients in a "slam dunk" scenario [2][3] - A "bull case" scenario includes an objective response rate of 15% to 20% or higher, median progression-free survival of at least five months, and Grade 3 diarrhea in less than 10% of patients [3] Group 3: Bear Case Scenario - The "bear case" scenario defined by H.C. Wainwright includes an objective response rate of 10% or lower and median progression-free survival of only two to three months, providing investors with clear metrics to assess the upcoming clinical results [4] Group 4: Company Overview - CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing masked biologics that conditionally activate in the tumor microenvironment, emphasizing its oncology focus [4]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...